MedTrace Logo

Haptoglobin Phenotype and Cardiovascular Complications in Diabetic Patients

NCT00448487 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3054

Last updated 2015-06-12

No results posted yet for this study

Summary

3054 diabetic patients were screened for Haptoglobin Phenotype as part of the ICARE study (NCT00220831) and composite the I CARE Registry, 1434 Hp 2-2 patients were treated as part of the I CARE study with vitamin E vs. Placebo, this study was recently terminated due to significant differences between the groups and data was sent to publication. All other patients were passively followed since April 2005 for cardiovascular events. We have decided to continue and follow these patients till end of December 2007 to determine the incidence of CVD in theses patients which are pre stratified by Haptoglobin Phenotype.

Conditions

Sponsors & Collaborators

  • Clalit Health Services

    collaborator OTHER

  • Dr. Shany Blum

    lead OTHER

Principal Investigators

  • Shany Blum, M.D. M.Sc. · Technion, Israel Institute of Technology

  • Uzi Milman, M.D. · Clalit Health Services

  • Chen Shapira, M.D. · Clalit Health Services

  • Andrew P Levy, M.D. Ph.D. · Technion, Israel Institute of Technology

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00448487 on ClinicalTrials.gov